U.S. Markets closed

Amarin allowed key ANCHOR '520 patent, says Jefferies

Jefferies said it learned that the U.S. patent office allowed the key ANCHOR '520 patent, which is views as a major positive for Amarin. Further, Jefferies firm thinks Amarin’s non-dilutive debt financing and decision to hire a salesforce to launch Vascepa in Q1 should have been expected given the lack of clarity around FDA exclusivity. Jefferies keeps a Buy rating on the stock with a $28 price target.